Navigation Links
BioLife Solutions Announces Expanded Customer Base in the High Growth Regenerative Medicine Market

BOTHELL, Wash., June 1, 2011 /PRNewswire/ -- BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today issued an update on the growing number and quality of life science organizations using the Company's products.   These customers are all now purchasing HypoThermosol® and/or CryoStor® to support the development of new regenerative medicine products and therapies.  


Mike Rice, Chairman and CEO, commented on the growing adoption of BioLife's best-in-class HypoThermosol storage/shipping media and CryoStor freeze media by stating, "We continue to acquire new regenerative medicine customers who are aware of growing regulatory oversight of reagents used in the manufacturing, storage, and delivery processes of novel cell- and tissue-based products.  Our GMP-manufactured, serum-free, protein-free biopreservation media products have a robust quality profile and proven superior preservation efficacy across a broad spectrum of cell and tissue types.  The cost, quality, and performance of our products are all highly aligned with the requirements of the regenerative medicine market."  

Now totaling more than several hundred accounts, BioLife's regenerative medicine customer base is comprised of private and public companies and hospital-based transplant centers including Cardio 3 Biosciences, Children's Cancer Research Institute (Vienna, Austria), DCPrime BV, and Intercytex Ltd.

MedMarket Diligence, LLC, estimates that the current worldwide market for regenerative medicine products and services is growing at 20% annually.  Scientia Advisors, a biotech and medical consulting firm, estimates that the market for regenerative medicine technologies that repair the body could swell to $15-20 billion over the next 15 years. Axis Research Mind estimates the global market value for cryopreservation equipment used in the stem cells industry to be worth $2.2 billion by 2015, representing a compound annual growth rate of about 24%. Freezers represent more than half of the cryopreservation equipment market value, with biopreservation reagents accounting for close to 20% of the total market.  Accordingly, BioLife's addressable market is estimated at nearly $450 million in 2015.

Rice continued, "As regulatory scrutiny increases, we expect pre-formulated biopreservation media products such as our HypoThermosol and CryoStor to continue to displace 'home-brew' preservation cocktails.  While the regenerative medicine market is still in an early phase, our technologies are embedded into numerous clinical trial stage products and we see significant upside in the Company's financial operations from fulfilling potential increased product demand, should our customers' products gain regulatory and marketing approvals."

BioLife recently exhibited at the 17th International Society for Cellular Therapy Annual Meeting in Rotterdam, Netherlands.  Aby J. Mathew, Ph.D., Senior Vice President & Chief Technology Officer, presented a tutorial titled, Biopreservation and Stability Considerations for Cellular Therapies – Clinical Applications of HypoThermosol® and CryoStor® as Ancillary or Excipient Reagents.  In this presentation, Dr. Mathew provided examples of customer adoption of BioLife's patented biopreservation media products and their underlying scientific foundation.  The presentation may be viewed here:  The Spring 2011 issue of BioPreservation Today®, which includes listings of development stage regenerative medicine applications incorporating CryoStor and HypoThermosol, can be found here:

About BioLife Solutions, Inc.:Founded in 1998, with the initial development of its intellectual property base in 1992, BioLife Solutions develops, manufactures, and markets patented hypothermic storage/transport and cryopreservation (freeze) media products for cells, tissues, and organs, and also performs contract media manufacturing and contract research and development. The Company's proprietary HypoThermosol and CryoStor platform of biopreservation media products are marketed to academic research institutions, hospitals, and commercial companies involved in cell therapy, tissue engineering, cord blood banking, drug discovery, and toxicology testing. BioLife's GMP products are serum-free and protein-free, fully defined, and pre-formulated to reduce preservation-induced, delayed-onset cell damage and death.  US FDA Master Files are available for cross-reference. BioLife's enabling technology provides research and clinical customers significantly extended storage stability and improved post-preservation viability and recovery of cells, tissues, and organs. For more information please visit

Safe Harbor Statement

This shareholder communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about BioLife Solutions, Inc. (the "Company") and its future operating results, strategies, and product development plans. These forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially from the results expressed or implied in these forward-looking statements. Factors that may cause or contribute to such differences are more fully discussed, as are other factors, in Part I, Item1A. "Risk Factors" of the Company's Form 10-K for the fiscal year ended December 31, 2010, which is on file with the SEC and available at In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While the Company may elect to update forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as may be legally necessary, even if the Company's estimates should change.Media Relations:Investor Relations:Len Hall

Matt ClawsonAllen & Caron Inc

Allen & Caron Inc(949) 474-4300


SOURCE BioLife Solutions, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLife Solutions Announces Record Quarterly Revenue
2. BioLife Solutions Increases 2011 Financial, Scientific, Technical Support of the Regenerative Medicine Industry
3. Oclaro Provides Complete Fiber Laser Diode Solutions Portfolio; Outlines Future Innovation and Technology Advancements
4. Asante Solutions Receives FDA Clearance for Pearl™ Insulin Pump
5. Zen Holding Corp. Signs LOI to Acquire Millennium Healthcare Solutions Inc.
6. Sales Agreement with GHX Adds Certain GHX Cost Saving and Revenue-Increasing Solutions to Medical Surgical Solutions Product Offerings
7. Elekta to Demonstrate Advanced Solutions for Managing Cancer Safely and Effectively at ESTRO 2011
8. Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change
9. Neusoft to Invest in Israeli Medical Solutions Company for Accelerating Expansion in Global Healthcare Service Market
10. OnPoint Medical Diagnostics, Inc. and Vertical Health Solutions, Inc. Complete Reverse Merger
11. United Imaging Healthcare Leverages Samplifys Analog Front-End Solutions to Deliver New Portable Ultrasound System with Superior Image Quality
Post Your Comments:
(Date:11/30/2015)... KIRKLAND, Wash. , Nov. 30, 2015 /PRNewswire/ ... of Post-Processing services, is pleased to announce a ... of medical imaging services. Building on its ISO-9001:2008 ... adopted and implemented comprehensive Core Lab protocols and ... wide variety of research activities.  Their Core Lab ...
(Date:11/30/2015)... 30, 2015 Mexico Healthcare and Life Sciences ... Report 2015 . --> Pharmaboardroom releases its new 98-page ... Latin America , a country of over 122 million ... of over 122 million people. --> It offers companies, ... life sciences insights into the second largest pharma and healthcare market ...
(Date:11/30/2015)... , November 30, 2015 Elbit ... the "Company") announced today that it was informed by InSightec ... Drug Safety (MFDS) has approved its Exablate Neuro system ... --> --> Insightec,s Exablate Neuro ... alternative that combines two technologies: Focused Ultrasound, which is ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... , ... The Foundation for Breast and Prostate Health (FBPH)—a ... with the award-winning creator and writer of Downton Abbey Julian Fellowes to host ... Union League of Philadelphia. , The benefit, titled “An Evening with Julian ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... Specialty Ingredients (ASI) as their exclusive channel partner for the Nutraceutical Specialties products ... markets in the US, effective immediately. , “We are pleased to announce ...
(Date:11/30/2015)... ... November 30, 2015 , ... California-based i2i Systems, a ... today that Michigan-based Family Health Center (FHC) has selected i2iTracks as their population ... was awarded the largest Affordable Care Act grant for Federally Qualified Health Centers ...
(Date:11/30/2015)... PITTSBURGH, PA (PRWEB) , ... November 30, 2015 , ... ... quality of life in the womb. "My last baby had high blood pressure due ... way for mothers to protect their babies from noise pollution as well as radio ...
(Date:11/30/2015)... ... November 30, 2015 , ... In an interview with Andy ... a top ophthalmologist on Long Island’s east end. During the broadcast, entitled “Eyes: the ... and treatment of glaucoma and cataracts, and how a visit with his grandmother to ...
Breaking Medicine News(10 mins):